MARKET

NRXP

NRXP

Nrx Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5730
-0.0060
-1.04%
After Hours: 0.5605 -0.0125 -2.18% 19:54 06/29 EDT
OPEN
0.5899
PREV CLOSE
0.5790
HIGH
0.5900
LOW
0.5513
VOLUME
191.38K
TURNOVER
0
52 WEEK HIGH
26.24
52 WEEK LOW
0.4899
MARKET CAP
38.19M
P/E (TTM)
-0.0748
1D
5D
1M
3M
1Y
5Y
NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals"), a clinical-stage biopharmaceutical company, today announced its interim Chief Executive Officer, Robert Besthof, and other executive leaders will be presenting a virtual update to the compa...
PR Newswire · 6d ago
What's Next For NRx Pharma As FDA Denies Breakthrough Therapy Tag For COVID-19 Therapy
Benzinga · 06/13 13:02
BRIEF-NRX Pharmaceuticals Says FDA Denied Breakthrough Therapy Designation Request For Zyesami (Aviptadil)
reuters.com · 06/11 02:53
NRx Pharmaceuticals Provides Update on Breakthrough Therapy Designation (BTD) Request for ZYESAMI® (aviptadil)
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, NRx Pharmaceuticals), ("NRXP" or the "Company"), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) denied the Breakthrough Therapy designation (BTD) request...
PR Newswire · 06/11 02:47
BRIEF-NRX Pharma Files For Mixed Shelf Of Up To $150 Million
reuters.com · 06/09 10:20
NRx Pharmaceuticals names Seth Van Voorhees as CFO
NRx Pharmaceuticals (NASDAQ:NRXP) said that the company's board has appointed Seth Van Voorhees, Ph.D. as CFO and Treasurer effective June 13, 2022. Dr. Van Voorhees most recently served as CFO
Seekingalpha · 06/08 04:56
BRIEF-NRX Pharmaceuticals Appoints Seth Van Voorhee As Chief Financial Officer And Treasurer
reuters.com · 06/08 00:04
69 Biggest Movers From Friday
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
Benzinga · 06/06 09:31
More
No Data
Learn about the latest financial forecast of NRXP. Analyze the recent business situations of Nrx Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
No Data
About NRXP
NRX Pharmaceuticals, Inc., formerly Big Rock Partners Acquisition Corp., is a patient-focused, clinical stage pharmaceutical company. The Company is focused on developing NRX-101. NRX-101 is an oral therapeutic for the treatment of Acute Suicidal Behavior/Ideation (ASIB) in Bipolar Disorder and ZYESAMI (aviptadil), an intravenous and inhaled drug to treat respiratory failure in COVID-19. NRX-101 is designed to offer an oral, rapid-onset and sustained home-use therapy that can extend ketamine’s anti-suicidal benefit and reduce the side effects of ketamine. The Company combines D-cycloserine (DCS), a N-methyl-D-aspartate (NMDA) receptor modulator, and lurasidone, a 5-HT2a receptor antagonist. NRX-101 is in Phase III of clinical testing.

Webull offers kinds of NRX Pharmaceuticals Inc stock information, including NASDAQ:NRXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRXP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NRXP stock methods without spending real money on the virtual paper trading platform.